CIK细胞联合常规治疗对肾透明细胞癌患者的临床疗效

目的:探讨DC-CIK细胞治疗肾透明细胞癌临床疗效及治疗次数对患者预后的影响.方法:回顾性分析2004年1月至2011年6月在福建省肿瘤医院诊疗的100例肾透明细胞癌患者,其中63例在福建省肿瘤生物治疗重点实验室进行自体DC-CIK细胞免疫治疗联合常规治疗为DC-CIK细胞治疗组,其余37例未经DC-CIK细胞治疗为对照组,比较两组患者的5年DFS和OS.治疗组按照DC-CIK细胞治疗疗程数分成≤3个疗程组及＞3个疗程组,分析DC-CIK细胞治疗疗程数对肾透明细胞癌患者5年DFS和OS的相关性.结果:DC-CIK细胞治疗组患者5年OS较对照组明显提高(81.05％ vs 60.29％,P＜0.05),但5年DFS无显著性差异(P＞0.05);DC-CIK细胞治疗疗程数＞3个的患者5年OS较对照组明显提高(P＜0.05),但5年DFS无显著性差异(P＞0.05).结论:自体DC-CIK细胞回输联合常规治疗手段治疗肾透明细胞癌更有生存优势,且DC-CIK细胞治疗疗程数与肾透明细胞癌患者的预后密切相关.

Clinical evaluation of dendritic cell cytokine induced killer cells immunotherapy combined with conventional treatment in patients with renal carcinoma

Objective:To evaluate the clinical efficacy of adjuvant dendrtic cell (DC)-cytokine-induced killer (CIK) cells immunotherapy and the effect of DC-CIK cells treatment courses on the prognosis of patients with renal clear cell carcinoma.Methods:One hundred patients with renal clear cell carcinoma treated in Fujian Provincial Tumor Hospital from Jan,2004 to Jun,2011 were included in this retrospective study;63 patients received DC-CIK cells immunotherapy combined with conventional therapy were regarded as DC-CIK cells treatment group,while the other 37 patients didnt receive DC-CIK cells therapy were regarded as control group.The 5-year DFS and OS of the two groups were compared.The treatment group was further sub-grouped according to the course ＞ 3 and course ≤3,and the 5-year DFS and OS were further compared between the two sub-groups.Results:Survival analysis showed the 5-years overall survival (OS) rate was significantly higher in the DC-CIK group compared with the control group (81.05 ％ vs 60.29％,P ＜ 0.05),however,there was no significant difference in 5-year DFS rate between two groups.Further subgroup analysis stratified according to the course of DC-CIK cells treatment showed that the 5-years OS was significantly improved in the group with course greater than 3 (P ＜ 0.05),although there was no significant difference in 5-years DFS rate between two subgroups (P ＞ 0.05).Conclusion:Our results demonstrated that renal carcinoma patients could benefit from autologous DC-CIK cells immunotherapy in combination with conventional therapies in terms of increasing overall survival.And the course of DC-CIK cells treatment is closely related with the prognosis of patients with renal cell carcinoma.